OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires $69,879.39 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 47,537 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were acquired at an average cost of $1.47 per share, with a total value of $69,879.39. Following the purchase, the chief executive officer now directly owns 213,234,014 shares of the company’s stock, valued at approximately $313,454,000.58. The trade was a 0.02 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.48 per share, with a total value of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.59 per share, with a total value of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.56 per share, with a total value of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost purchased 199,072 shares of OPKO Health stock. The shares were acquired at an average cost of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were purchased at an average cost of $1.50 per share, with a total value of $420,274.50.

OPKO Health Stock Up 0.7 %

OPKO Health stock opened at $1.51 on Friday. OPKO Health, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $1.76. The stock has a market cap of $1.03 billion, a PE ratio of -7.95 and a beta of 1.63. The firm’s 50-day simple moving average is $1.52 and its 200 day simple moving average is $1.52. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.13. The business had revenue of $173.60 million for the quarter, compared to analyst estimates of $181.32 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. Research analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Institutional Trading of OPKO Health

Several hedge funds have recently added to or reduced their stakes in OPK. American Century Companies Inc. bought a new stake in OPKO Health in the second quarter worth about $112,000. Squarepoint Ops LLC bought a new stake in OPKO Health in the second quarter worth about $592,000. Algert Global LLC bought a new stake in OPKO Health in the second quarter worth about $44,000. SG Americas Securities LLC raised its position in shares of OPKO Health by 1,086.9% in the third quarter. SG Americas Securities LLC now owns 135,856 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 124,410 shares during the period. Finally, Exchange Traded Concepts LLC raised its position in shares of OPKO Health by 135.7% in the third quarter. Exchange Traded Concepts LLC now owns 387,108 shares of the biotechnology company’s stock valued at $577,000 after purchasing an additional 222,869 shares during the period. Institutional investors own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on OPK. Barrington Research reissued an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Wednesday, January 8th. Finally, StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.